We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

60 hedge funds and large institutions have $173M invested in Xenon Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

0.73% less ownership

Funds ownership: 68.88% → 68.15% (-0.73%)

4% less capital invested

Capital invested by funds: $180M → $173M (-$7.03M)

5% less funds holding

Funds holding: 63 → 60 (-3)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
60
Holders Change
-3
Holders Change %
-4.76%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
8
Increased
18
Reduced
13
Closed
10
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$9K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$6.25M
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.18M
3
NMC
NEA Management Company
Maryland
+$1.75M
4
ACP
Acuta Capital Partners
California
+$1.43M
5
Russell Investments Group
Russell Investments Group
United Kingdom
+$753K

Top Sellers

1
SFM
Sphera Funds Management
Israel
-$5.42M
2
SSA
Schonfeld Strategic Advisors
New York
-$5.08M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.05M
4
SCM
Stonepine Capital Management
Oregon
-$1M
5
IPC
Invesco Private Capital
New York
-$808K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$23.7M – – –
BI
2
BVF Inc
California
$17.2M -$451K -47,174 -3%
VC
3
Vivo Capital
California
$13.9M – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$12.8M – – –
EAM
5
Eventide Asset Management
Massachusetts
$12.6M +$6.25M +653,409 +105%
Capital International Investors
6
Capital International Investors
California
$10.4M – – –
Capital World Investors
7
Capital World Investors
California
$9.5M – – –
ACM
8
Aquilo Capital Management
California
$9.38M – – –
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$9.12M +$718K +75,000 +9%
ACP
10
Acuta Capital Partners
California
$6.92M +$1.43M +149,000 +27%
O
11
OrbiMed
New York
$6.26M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$4.69M +$30.6K +3,200 +0.7%
Citadel Advisors
13
Citadel Advisors
Florida
$4.32M -$2.05M -214,443 -33%
DCM
14
DAFNA Capital Management
California
$3.26M – – –
GPCM
15
Granite Point Capital Management
Massachusetts
$2.99M – – –
BlackRock
16
BlackRock
New York
$2.55M -$85.8K -8,963 -3%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$2.24M +$2.18M +227,539 New
EP
18
Eversept Partners
New York
$2.21M – – –
NMC
19
NEA Management Company
Maryland
$1.8M +$1.75M +182,754 New
AGA
20
Altrinsic Global Advisors
Connecticut
$1.77M +$191K +20,000 +13%
DMK
21
David M. Knott
$1.77M – – –
State of New Jersey Common Pension Fund D
22
State of New Jersey Common Pension Fund D
New Jersey
$1.53M – – –
AS
23
Altshuler Shaham
Israel
$1.48M +$58.9K +6,151 +4%
USAA
24
United Services Automobile Association
Texas
$996K +$23K +2,400 +2%
GIM
25
Granahan Investment Management
Massachusetts
$969K -$99.7K -10,420 -10%
1
2 3

XENE Hedge Fund Activity: Q2 2019 in Review

60 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2019, worth a combined $173M — down 3.9% from $180M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of XENE and 8 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Eventide Asset Management, adding an estimated $6.25M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.42M sold.

  • 60 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2019, down from 63 in Q1 2019.
  • Funds reported $173M of Xenon Pharmaceuticals stock for Q2 2019, down 3.9% quarter-over-quarter.
  • 8 funds opened new Xenon Pharmaceuticals positions in Q2 2019 and 10 closed out, a net change of -2 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2019 was Eventide Asset Management, an estimated $6.25M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2019 was Sphera Funds Management, an estimated $5.42M sold.

Based on aggregated 13F filings for Q2 2019.